3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pharmacovigilance is the science of monitoring the effects of medicinal products to identify and evaluate potential adverse reactions and provide necessary and timely risk mitigation measures. Intelligent automation technologies have a strong potential to automate routine work and to balance resource use across safety risk management and other pharmacovigilance activities. While emerging technologies such as artificial intelligence (AI) show great promise for improving pharmacovigilance with their capability to learn based on data inputs, existing validation guidelines should be augmented to verify intelligent automation systems. While the underlying validation requirements largely remain the same, additional activities tailored to intelligent automation are needed to document evidence that the system is fit for purpose. We propose three categories of intelligent automation systems, ranging from rule-based systems to dynamic AI-based systems, and each category needs a unique validation approach. We expand on the existing good automated manufacturing practices, which outline a risk-based approach to artificially intelligent static systems. Our framework provides pharmacovigilance professionals with the knowledge to lead technology implementations within their organizations with considerations given to the building, implementation, validation, and maintenance of assistive technology systems. Successful pharmacovigilance professionals will play an increasingly active role in bridging the gap between business operations and technical advancements to ensure inspection readiness and compliance with global regulatory authorities.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Natural language processing: an introduction.

          To provide an overview and tutorial of natural language processing (NLP) and modern NLP-system design. This tutorial targets the medical informatics generalist who has limited acquaintance with the principles behind NLP and/or limited knowledge of the current state of the art. We describe the historical evolution of NLP, and summarize common NLP sub-problems in this extensive field. We then provide a synopsis of selected highlights of medical NLP efforts. After providing a brief description of common machine-learning approaches that are being used for diverse NLP sub-problems, we discuss how modern NLP architectures are designed, with a summary of the Apache Foundation's Unstructured Information Management Architecture. We finally consider possible future directions for NLP, and reflect on the possible impact of IBM Watson on the medical field.
            Bookmark
            • Record: found
            • Abstract: not found
            • Book: not found

            Introduction to Machine Learning

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing

              Automation of pharmaceutical safety case processing represents a significant opportunity to affect the strongest cost driver for a company's overall pharmacovigilance budget. A pilot was undertaken to test the feasibility of using artificial intelligence and robotic process automation to automate processing of adverse event reports. The pilot paradigm was used to simultaneously test proposed solutions of three commercial vendors. The result confirmed the feasibility of using artificial intelligence–based technology to support extraction from adverse event source documents and evaluation of case validity. In addition, the pilot demonstrated viability of the use of safety database data fields as a surrogate for otherwise time‐consuming and costly direct annotation of source documents. Finally, the evaluation and scoring method used in the pilot was able to differentiate vendor capabilities and identify the best candidate to move into the discovery phase.
                Bookmark

                Author and article information

                Contributors
                Kristof.Huysentruyt@ucb.com
                Journal
                Drug Saf
                Drug Saf
                Drug Safety
                Springer International Publishing (Cham )
                0114-5916
                1179-1942
                1 February 2021
                1 February 2021
                2021
                : 44
                : 3
                : 261-272
                Affiliations
                [1 ]Patient Safety, UCB, Brussels, Belgium
                [2 ]R&D IT, MSD, Prague, Czech Republic
                [3 ]RGITSC Software Validation, Roche Polska Sp. z o.o., Warsaw, Poland
                [4 ]GRID grid.497530.c, ISNI 0000 0004 0389 4927, Global Medical Organization, Janssen Research & Development, LLC a division of Johnson & Johnson, ; Horsham, PA USA
                [5 ]PV Information Management, Astellas, Chicago, IL USA
                [6 ]GRID grid.417815.e, ISNI 0000 0004 5929 4381, Information Technology, AstraZeneca, ; Macclesfield, UK
                [7 ]GRID grid.419971.3, WorldWide Patient Safety, , Bristol-Myers Squibb Company, ; Princeton, NJ USA
                [8 ]GRID grid.417993.1, ISNI 0000 0001 2260 0793, Safety Management, , Global Regulatory Affairs and, Merck & Co., Inc., ; Kenilworth, NJ USA
                [9 ]GRID grid.410513.2, ISNI 0000 0000 8800 7493, Worldwide Safety, , Pfizer Inc, ; Peapack, NJ USA
                [10 ]GRID grid.419971.3, WorldWide Patient Safety, , Bristol-Myers Squibb Company, ; Princeton, NJ USA
                Author information
                http://orcid.org/0000-0002-2641-9382
                Article
                1030
                10.1007/s40264-020-01030-2
                7892696
                33523400
                d75eef31-af12-49cd-94c7-f6a6b2410488
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 1 December 2020
                Categories
                Leading Article
                Custom metadata
                © Springer Nature Switzerland AG 2021

                Comments

                Comment on this article